GlycoMimetics
(NASDAQ) GLYC
GlycoMimetics Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$0.00
Net Income (TTM)
$152.29M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
GLYC News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout GlycoMimetics
Industry
Biotechnology
Sector
Health CareEmployees
44
CEO
Joshua T. Brumm
Website
www.crescentbiopharma.comHeadquarters
Rockville, MD 20850, US
GLYC Financials
Key Financial Metrics (TTM)
Gross Margin
96%
Operating Margin
-3%
Net Income Margin
-3%
Return on Equity
-1%
Return on Capital
-69%
Return on Assets
-59%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$0.00
Operating Income
$152.63M
EBITDA
$149.67M
Operating Cash Flow
$71.53M
Capital Expenditure
$919.00K
Free Cash Flow
$72.45M
Cash & ST Invst.
$213.19M
Total Debt
$1.64M
GlycoMimetics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
-100.0%
Gross Profit
$0.00
-100.0%
Gross Margin
0.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
4
N/A
Net Income
$149.94M
-1976.0%
EBITDA
$150.78M
-1311.1%
Quarterly Fundamentals
Net Cash
$211.55M
+1885.7%
Accounts Receivable
$18.00M
+13079.1%
Inventory
$0.00
N/A
Long Term Debt
$1.21M
N/A
Short Term Debt
$435.00K
+225.4%
Return on Assets
-58.74%
N/A
Return on Invested Capital
-68.95%
N/A
Free Cash Flow
$26.93M
-627.6%
Operating Cash Flow
$26.74M
-622.4%